Skip to main content
. 2019 Jun 29;44(13):2195–2204. doi: 10.1038/s41386-019-0454-0

Fig. 4.

Fig. 4

Dorsomedial striatum infusions. a Effects of intra-DMS infusion of the DA D1 receptor antagonist SCH23390 (1 µg/side) and agonist SKF82958 (5 µg/side) on the behavioral measures of task performance. b Effects of intra-DMS infusion of the DA D1 receptor antagonist SCH23390 (1 µg/side) and agonist SKF82958 (5 µg/side) on the computational modeling parameters. c Effects of intra-DMS infusion of the DA D2 receptor antagonist raclopride (7.5 µg/side) and agonist quinpirole (5 µg/side) on the behavioral measures of task performance. d Effects of intra-DMS infusion of the DA D2 receptor antagonist raclopride (7.5 µg/side) and agonist quinpirole (5 µg/side) on the computational modeling parameters. The statistical range is denoted as: *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001. n = 8 rats